Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Receivables - Net (2022 - 2025)

Historic Receivables - Net for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $32000.0.

  • Corvus Pharmaceuticals' Receivables - Net fell 5428.57% to $32000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $32000.0, marking a year-over-year decrease of 5428.57%. This contributed to the annual value of $75000.0 for FY2024, which is 18846.15% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Receivables - Net of $32000.0 as of Q3 2025, which was down 5428.57% from $86000.0 recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Receivables - Net peaked at $588000.0 during Q4 2022, and registered a low of $11000.0 during Q3 2023.
  • Moreover, its 4-year median value for Receivables - Net was $52500.0 (2024), whereas its average is $102800.0.
  • Its Receivables - Net has fluctuated over the past 5 years, first tumbled by 9557.82% in 2023, then soared by 53636.36% in 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' Receivables - Net (Quarter) stood at $588000.0 in 2022, then plummeted by 95.58% to $26000.0 in 2023, then skyrocketed by 188.46% to $75000.0 in 2024, then tumbled by 57.33% to $32000.0 in 2025.
  • Its Receivables - Net was $32000.0 in Q3 2025, compared to $86000.0 in Q2 2025 and $79000.0 in Q1 2025.